Genetics & Epigenetics Library
Every article, presentation, spotlight, and news item we've tagged to Genetics & Epigenetics.
Showing 169–176 of 176
Biotech lands $45m to drug the undruggable
Unnatural Products raised $45 million to advance macrocyclic peptide therapeutics targeting intracellular protein interactions implicated in cardiometabolic, inflammatory, and age-related diseases. This technology addresses a critical gap in drug development by enabling selective modulation of previously inaccessible cellular pathways.
Half of how long we live might be in our genes
A twin-based study published in Science estimates genetic influence accounts for approximately 55% of human lifespan variation, with the remaining 45% shaped by diet, exercise, habits, and environmental factors. This finding reframes longevity as neither purely genetic nor purely behavioral, but rather a composite outcome where lifestyle interventions remain substantively meaningful within genetically-established boundaries.
Blood biomarkers detect cognitive decline before symptoms
DiamiR Biosciences will present three posters at the 2026 Alzheimer's Association International Conference focused on blood-based biomarkers for cognitive decline detection, including plasma APOE genotyping and circulating microRNA signatures. These biomarkers represent a shift toward non-invasive, early-stage identification of neurodegeneration risk before clinical symptoms manifest.
Mining the prodrome of neurodegeneration
Transformer-based analysis of electronic health records identified five distinct subtypes of Alzheimer's and Parkinson's disease, each with unique clinical trajectories, comorbidities, and genetic profiles. This stratification approach enables more precise disease understanding and potentially more targeted intervention strategies across the neurodegenerative disease landscape.
Ribo, Insilico partner to accelerate siRNA drug development using AI
Ribo and Insilico Medicine are collaborating to accelerate siRNA drug development by combining siRNA capabilities with AI-powered target discovery and molecule design. siRNA therapeutics can selectively silence disease-causing genes with rapid development timelines and extended therapeutic duration.
SuperAgers Challenge Genetic Destiny in Brain Aging
SuperAgers—individuals in their 80s and 90s with memory performance matching those in their 50s and 60s—carry the same genetic risk variants for Alzheimer's disease as cognitively average older adults, indicating that exceptional brain aging is not determined by inherited genetic advantage. This finding redirects focus from genetic destiny to the biological and behavioral mechanisms that actively protect cognitive function across the lifespan.
First Human Cellular Reprogramming Trial Cleared by the FDA
Life Biosciences has received FDA clearance to begin the first human trial of cellular reprogramming, testing ER-100 against age-related vision diseases. This represents the first clinical translation of partial reprogramming technology, moving a three-decade research program from laboratory validation into human application.
Estimating Vascular Age to Evaluate the Association Between Aging and Cardiovascular Disease
Vascular age acceleration, measured through a quantitative model, independently predicts cardiovascular disease risk beyond chronological age, with a 21–25% increased risk in those showing accelerated vascular aging. This metric enables earlier identification of individuals requiring intervention before overt disease manifestation.